Will I gain the weight back after stopping a GLP-1?

Often some of it, but it's not all-or-nothing. In withdrawal trials, people who switched to placebo regained about two-thirds of their lost weight, while real-world data shows just over half of people kept off some or all of their loss at 24 months. The difference is largely predictable: the people who keep the most off protected their muscle and built durable habits while on the drug.

Is it better to taper off or stop cold turkey?

A gradual taper with your prescriber generally beats stopping abruptly. Stepping the dose down lets appetite return in stages you can manage, rather than all at once. There's no official manufacturer taper protocol, so the schedule is individualized — the planner on this page gives a common, conservative version to discuss with your clinician.

What's the single biggest thing that prevents regain?

Muscle. It's metabolically active, so holding onto it keeps your daily calorie burn higher and makes maintenance far more forgiving after you stop. That's why protein and resistance training — plus catching muscle loss early — matter more than anything else on the way off.

Why do people stop GLP-1s?

Most often cost and supply, sometimes side effects, and sometimes because they've reached their goal. Whatever the reason, going in with a plan — a taper, protein, resistance training, and weekly weigh-ins — dramatically changes how much weight stays off.

Coming off? Do it on your terms.

Stopping a GLP-1: Will I Gain It Back?

Whether it's cost, supply, or you've reached your goal — how much weight stays off is largely in your control. Check your personal regain risk, then build a taper instead of quitting cold.

Check my regain risk Build my taper

Regain risk calculator

Your risk of significant regain — and the specific levers that lower it.

Will you gain it back?

Answer honestly — these are the factors that actually predict who keeps the weight off.

1. Do you do resistance training 2–3 times a week?

2. How are you planning to stop?

3. Are you hitting a daily protein target (about 1.2–1.6 g/kg)?

4. Did you lose weight at a controlled pace (about 1%/week or less)?

5. Have your everyday eating and activity habits genuinely changed?

Answer all 5 questions to see your regain risk. (0/5)

Educational risk estimate based on the factors most linked to keeping weight off — not a prediction of your personal result, and not medical advice. Any decision to stop or taper is one to make with your prescriber.

Tapering planner

A conservative step-down schedule to take to your prescriber.

Tapering Planner

A gradual step-down beats stopping cold. Here's a common schedule to take to your prescriber.

1. Your medication

2. Your current weekly dose

Your step-down schedule

~20 weeks · 4 wks/step

1
2.4 mg · weeks 1–4
2
1.7 mg · weeks 5–8
3
1 mg · weeks 9–12
4
0.5 mg · weeks 13–16
5
0.25 mg · weeks 17–20
Off — week 21 onward · maintain on habits

Wegovy's own titration climbs 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg. A taper generally walks the same ladder back down, holding at each step. Hold longer at any step where hunger surges or weight ticks up — and only continue down while things stay stable. There is no official manufacturer taper protocol; your prescriber sets the real plan.

Hold these the whole way down

Protein first, every meal (about 1.2–1.6 g/kg). This is what holds onto muscle as appetite returns.
Resistance training 2–3×/week — the strongest protection against regain.
Weigh in weekly. Catch drift early, while it's 2–3 lbs and easy to correct.
Expect appetite to come back at each step down. That's the taper working — plan meals so it doesn't run the show.

Get your maintenance calories & protein numbers

Educational schedule only — a common, conservative approach, not a prescription. Doses, timing, and whether to stop at all are decisions for you and your prescriber.

What the evidence actually says

Stopping does cause regain — on average

In withdrawal trials, stopping led to meaningful regain: in STEP 4, people switched to placebo regained about two-thirds of their lost weight over roughly a year, while those who continued semaglutide kept losing. The SURMOUNT-4 trial showed a similar pattern for tirzepatide.

But you are not the average

It isn't all-or-nothing: real-world data suggests just over half of people (roughly 52–56%, depending on the drug) kept off some or all of their loss at 24 months. The keepers tend to share two things — they protected muscle on the way down, and they built durable nutrition and activity habits while on the drug.

The through-line in every study: muscle and habits decide it. Before you taper, check whether your loss was fat or muscle, and read the full off-ramp guide.

Before you go

Maintenance & keeping it off

Your maintenance calories and protein.

Open

Fat-vs-muscle tracker

Did you keep the muscle?

Open

Side effects: am I normal?

Timeline & symptom checker.

Open

Frequently Asked Questions

Common questions and answers about our calculator

Sources

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical TrialRubino D, Abrahamsson N, Davies M, et al. JAMA. 2021;325(14):1414–1425. doi:10.1001/jama.2021.3224
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical TrialAronne LJ, Sattar N, Horn DB, et al. JAMA. 2024;331(1):38–48. doi:10.1001/jama.2023.24945
Wegovy (semaglutide) Prescribing InformationU.S. Food & Drug Administration (FDA). 2023.
Zepbound (tirzepatide) Prescribing InformationU.S. Food & Drug Administration (FDA). 2023.

Tool Information

Last reviewed

July 24, 2026

Reviewed by

Dr. Jaydeep Sanghani

Created by

Meet Akabari

Dr. Jaydeep Sanghani

MBBS, MD, DNB(Anaesth.), PDCC(CCM), DrNB(CCM)

AIIMS Bhubaneswar · AIIMS Rishikesh

Critical care specialist and anesthesiologist with advanced training from AIIMS. Reviews health calculators at Calqulate to ensure medical accuracy and evidence-based standards.

Verified Profile